GoalVest Advisory’s ADC Therapeutics ADCT Stock Holding History

GoalVest Advisory’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	-$71	–	361
2025 Q1	$71	Buy	+50	New	+$85	﹤0.01%	502

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GoalVest Advisory's ADCT Position: Q2 2025 in Review

GoalVest Advisory sold out of ADC Therapeutics (ADCT) in Q2 2025, closing a stake of 50 shares — an estimated $71 sold.

GoalVest Advisory first reported a position in ADCT in Q1 2025 and held it in 1 quarter. The position peaked at $71 in Q1 2025. 86 funds tracked by Wall St. Rank hold ADCT as of Q2 2025.

GoalVest Advisory reported no remaining ADC Therapeutics position as of Q2 2025 after selling out during the quarter.
GoalVest Advisory sold 50 ADC Therapeutics shares in Q2 2025, an estimated $71.
GoalVest Advisory first reported a position in ADC Therapeutics in Q1 2025 and held it in 1 quarter.
GoalVest Advisory's ADC Therapeutics position peaked at $71 in Q1 2025.
86 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2025.

Based on GoalVest Advisory's 13F filing for Q2 2025, filed 1 Aug 2025.